Cellectar Poised for Breakout with Key EMA Filing
AI Prediction of Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, with its proprietary Phospholipid Drug Conjugate™ (PDC) platform, is poised for significant clinical advancements in cancer treatment, focusing on its lead assets iopofosine I 131 and CLR 125. The upcoming EMA submission for iopofosine I 131 and the awaited early data from the CLR 125 study are key catalysts.
Cellectar Biosciences, a late-stage biopharmaceutical company, leverages its unique Phospholipid Drug Conjugate™ (PDC) platform to develop targeted therapies for cancer, with a focus on difficult-to-treat forms. Its lead asset, iopofosine I 131, is advancing towards a potential EMA submission for Waldenstrom macroglobulinemia, which could significantly impact its valuation. Concurrently, CLR 125, targeting triple-negative breast cancer (TNBC), is expected to release early clinical data, potentially validating the company's PDC platform further. These developments, coupled with a strategic focus on solid tumors, position Cellectar at a critical juncture. Success in these areas could drive substantial appreciation in CLRB's market value.
CLRB Report Information
Prediction Date2026-03-14
Close @ Prediction$3.20
Mkt Cap21m
IPO DateN/a
AI-derived Information
Recent News for CLRB
- Jul 30, 8:05 am — Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026 (GlobeNewswire RSS)
- Jul 15, 7:30 am — Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers (GlobeNewswire RSS)
- Jun 1, 8:05 am — Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenstrom Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
- Jun 1, 8:05 am — Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire RSS)
- May 14, 7:02 pm — Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
- May 14, 5:08 pm — Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary (Moby)
- May 14, 7:15 am — Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
- May 11, 11:45 am — Has Centene (CNC) Outpaced Other Medical Stocks This Year? (Quartz)
- May 11, 8:05 am — Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 (GlobeNewswire)
- May 5, 10:30 am — BC-Most Active Stocks (Associated Press)
- May 5, 10:21 am — Cellectar (CLRB) Phase 2b Data Shows Durable Responses in Waldenström Macroglobulinemia (InvestorsHub)
- May 5, 7:10 am — Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenstrom Macroglobulinemia (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest